CN110022893B - 用于癌症疗法的免疫原性化合物 - Google Patents

用于癌症疗法的免疫原性化合物 Download PDF

Info

Publication number
CN110022893B
CN110022893B CN201780074774.0A CN201780074774A CN110022893B CN 110022893 B CN110022893 B CN 110022893B CN 201780074774 A CN201780074774 A CN 201780074774A CN 110022893 B CN110022893 B CN 110022893B
Authority
CN
China
Prior art keywords
peptide
seq
amino acid
antigenic
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780074774.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110022893A (zh
Inventor
L·钱
A·马修
M·披查德
F·斯特罗兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enterome SA
Original Assignee
Enterome SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterome SA filed Critical Enterome SA
Priority to CN202311807705.XA priority Critical patent/CN117801066A/zh
Publication of CN110022893A publication Critical patent/CN110022893A/zh
Application granted granted Critical
Publication of CN110022893B publication Critical patent/CN110022893B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CN201780074774.0A 2016-10-07 2017-10-09 用于癌症疗法的免疫原性化合物 Active CN110022893B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311807705.XA CN117801066A (zh) 2016-10-07 2017-10-09 用于癌症疗法的免疫原性化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16192948.4 2016-10-07
EP16192948 2016-10-07
PCT/EP2017/075673 WO2018065623A2 (en) 2016-10-07 2017-10-09 Immunogenic compounds for cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311807705.XA Division CN117801066A (zh) 2016-10-07 2017-10-09 用于癌症疗法的免疫原性化合物

Publications (2)

Publication Number Publication Date
CN110022893A CN110022893A (zh) 2019-07-16
CN110022893B true CN110022893B (zh) 2023-12-29

Family

ID=57123864

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780074774.0A Active CN110022893B (zh) 2016-10-07 2017-10-09 用于癌症疗法的免疫原性化合物
CN202311807705.XA Pending CN117801066A (zh) 2016-10-07 2017-10-09 用于癌症疗法的免疫原性化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311807705.XA Pending CN117801066A (zh) 2016-10-07 2017-10-09 用于癌症疗法的免疫原性化合物

Country Status (9)

Country Link
US (2) US11478537B2 (enExample)
EP (1) EP3522915A2 (enExample)
JP (3) JP7116278B2 (enExample)
KR (2) KR102622188B1 (enExample)
CN (2) CN110022893B (enExample)
AU (3) AU2017339577B2 (enExample)
CA (1) CA3039322A1 (enExample)
IL (3) IL302345B2 (enExample)
WO (1) WO2018065623A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102622188B1 (ko) 2016-10-07 2024-01-05 엔터롬 에스.에이. 암 치료를 위한 면역원성 화합물
CN110049774A (zh) 2016-10-07 2019-07-23 恩特罗姆公司 肿瘤相关抗原表位的小型生物群序列变体
CN117801069A (zh) 2016-10-07 2024-04-02 恩特罗姆公司 用于癌症疗法的免疫原性化合物
FI3773689T3 (fi) 2018-04-11 2023-01-31 Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon
SI4021487T1 (sl) * 2019-11-15 2024-03-29 Enterome S.A., Antigenski peptidi za preprečevanje in zdravljenje b-celične malignosti
CN116234587A (zh) * 2020-07-13 2023-06-06 俄勒冈健康与科学大学 用于诱导免疫应答的免疫原性构建体、组合物和方法
CN112010960A (zh) * 2020-09-10 2020-12-01 热休(厦门)细胞生物科技有限公司 一种肿瘤抗原复合物体外致敏dc、t细胞获得肿瘤特异性杀伤细胞ctl及其制备方法
US20220383996A1 (en) * 2021-05-27 2022-12-01 Amazon Technologies, Inc. Assigning peptides to peptide groups for vaccine development

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1954217A (zh) * 2004-02-06 2007-04-25 国立健康与医学研究所 衍生自gp41的多肽、含有所述多肽的疫苗组合物以及用于治疗个体HIV病毒感染的用途

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5550214A (en) * 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
DK1163000T3 (da) 1999-03-19 2008-04-28 Glaxosmithkline Biolog Sa Vacciner imod antigener fra bakterier
EP1165796A2 (en) 1999-04-09 2002-01-02 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
ATE512666T1 (de) 1999-06-29 2011-07-15 Epimmune Inc Hla-bindende peptide und ihre verwendungen
JP2003530083A (ja) * 1999-12-10 2003-10-14 エピミューン インコーポレイテッド ペプチドおよび核酸組成物を使用する、ＨＥＲ２／ｎｅｕに対する細胞性免疫応答の誘導
US20020197266A1 (en) 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2
AU2000232427A1 (en) 2000-02-23 2001-09-03 Epimmune Inc. HLA binding peptides and their uses
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
EP1496923A4 (en) 2002-03-22 2005-10-19 Penn State Res Found IMMUNOTHERAPY AGAINST CANCER
EP1578432A4 (en) 2002-10-03 2008-07-30 Epimmune Inc HLA BINDING PEPTIDES AND USES THEREOF
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
US7666622B2 (en) 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
CA2672215A1 (en) 2006-12-11 2008-06-19 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
JP2010190572A (ja) 2007-06-01 2010-09-02 Sapporo Medical Univ ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
CN101835792B (zh) 2007-08-20 2015-04-15 肿瘤疗法科学股份有限公司 Foxm1肽和包含foxm1肽的药剂
WO2010018136A1 (en) 2008-08-12 2010-02-18 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Minigene comprising htpa signal peptide, t-cell epitopes, e. coli ltb and furin sensitive linkers
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
WO2010129033A2 (en) * 2009-04-29 2010-11-11 Calmune Corporation Modified antibodies for passive immunotherapy
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
WO2011140284A2 (en) 2010-05-04 2011-11-10 Fred Hutchinson Cancer Research Center Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses
EP2608799B1 (en) 2010-08-24 2018-12-12 University of Pittsburgh - Of the Commonwealth System of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
ES2887580T3 (es) 2012-03-19 2021-12-23 Stemline Therapeutics Inc Métodos para el tratamiento y seguimiento del estado del cáncer
WO2013148147A1 (en) 2012-03-26 2013-10-03 The U.S.A., As Represented By The Secretary Dept. Of Health And Human Services Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
SI3536334T1 (sl) 2012-05-16 2021-11-30 Stemline Therapeutics Inc. Cepiva proti raku, ki ciljajo na rakave matične celice
US20140141044A1 (en) * 2012-11-12 2014-05-22 Dana-Farber Cancer Institute, Inc. Cord Colitis Syndrome Pathogen
US9758807B2 (en) 2012-12-05 2017-09-12 SOLA Biosciences, LLC Protein expression enhancing polypeptides
US9764037B2 (en) 2012-12-06 2017-09-19 Victoria Link Limited Conjugate compounds
KR20160016725A (ko) * 2014-08-05 2016-02-15 주식회사 유영제약 암 세포에 과발현되는 IL13Rα2에 특이적으로 결합하는 키메라 항원 수용체로 변형된 T 세포
WO2016133779A1 (en) 2015-02-16 2016-08-25 The Trustees Of The University Of Pennsylvania A fully-human t cell receptor specific for the 369-377 epitope derived from the her2/neu (erbb2) receptor protein
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
CN108026513A (zh) * 2015-03-31 2018-05-11 新加坡科技研究局 树突状细胞的抗原加载的方法和疫苗
WO2017203526A1 (en) 2016-05-23 2017-11-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of diagnosing cancer using cancer testis antigens
KR102622188B1 (ko) 2016-10-07 2024-01-05 엔터롬 에스.에이. 암 치료를 위한 면역원성 화합물
CN117801069A (zh) 2016-10-07 2024-04-02 恩特罗姆公司 用于癌症疗法的免疫原性化合物
CN110049774A (zh) 2016-10-07 2019-07-23 恩特罗姆公司 肿瘤相关抗原表位的小型生物群序列变体
EP3694541A2 (en) 2017-10-09 2020-08-19 Enterome S.A. Microbiota sequence variants of tumor-related antigenic epitopes
FI3773689T3 (fi) 2018-04-11 2023-01-31 Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon
EP3773673A2 (en) 2018-04-11 2021-02-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
WO2021074389A1 (en) 2019-10-16 2021-04-22 Enterome S.A. Immunogenic compounds for treatment of adrenal cancer
SI4021487T1 (sl) 2019-11-15 2024-03-29 Enterome S.A., Antigenski peptidi za preprečevanje in zdravljenje b-celične malignosti

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1954217A (zh) * 2004-02-06 2007-04-25 国立健康与医学研究所 衍生自gp41的多肽、含有所述多肽的疫苗组合物以及用于治疗个体HIV病毒感染的用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: implication in the identification of cryptic tumor epitopes;S Tourdot等;《Eur J Immunol》;20001231;第30卷(第11期);摘要、第3412-3415页、第3417页的讨论 *
PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses;Wenxue Ma等;《Int J Nanomedicine》;20120315;摘要、第1477-1483页 *
Recognition of Six-Transmembrane Epithelial Antigen of the Prostate–Expressing Tumor Cells by Peptide Antigen–Induced Cytotoxic T Lymphocytes;David A. Rodeberg等;《Clin Cancer Res》;20050615;第11卷(第12期);摘要、第4545右栏最后1段-第4546页、第4550-4551页的讨论 *

Also Published As

Publication number Publication date
US12263210B2 (en) 2025-04-01
AU2017339577B2 (en) 2021-12-02
JP7331207B2 (ja) 2023-08-22
IL296165B2 (en) 2023-10-01
IL302345B2 (en) 2024-12-01
IL265751A (en) 2019-05-30
JP7648311B2 (ja) 2025-03-18
US20230201322A1 (en) 2023-06-29
KR20240007316A (ko) 2024-01-16
AU2017339577A1 (en) 2019-05-02
AU2023222999A1 (en) 2023-09-21
EP3522915A2 (en) 2019-08-14
KR20190066028A (ko) 2019-06-12
US11478537B2 (en) 2022-10-25
CN117801066A (zh) 2024-04-02
IL296165A (en) 2022-11-01
IL265751B (en) 2022-10-01
CN110022893A (zh) 2019-07-16
AU2022200872B2 (en) 2023-06-29
KR102686875B1 (ko) 2024-07-19
IL265751B2 (en) 2023-02-01
AU2022200872A1 (en) 2022-03-03
CA3039322A1 (en) 2018-04-12
AU2023222999B2 (en) 2025-07-24
WO2018065623A2 (en) 2018-04-12
JP2022120137A (ja) 2022-08-17
IL302345B1 (en) 2024-08-01
JP2019534884A (ja) 2019-12-05
IL302345A (en) 2023-06-01
JP2023156414A (ja) 2023-10-24
KR102622188B1 (ko) 2024-01-05
JP7116278B2 (ja) 2022-08-10
WO2018065623A3 (en) 2018-05-31
US20200113983A1 (en) 2020-04-16
IL296165B1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
CN112118863B (zh) 用于预防和治疗癌症的抗原肽
CN110022893B (zh) 用于癌症疗法的免疫原性化合物
US12447201B2 (en) Immunogenic compounds for cancer therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment